The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic miceZi Li(Juntendo University), Yusuke Suzuki(Juntendo University)FEBS Open BioOctober 24, 202010.1002/2211-5463.13014Cited by 13SaveCiteExport RISWatch citationsRelated PapersAssociation of advanced glycation end products with sarcopenia and frailty in chronic kidney disease|Scientific Reports|2020|64Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis|Clinical Kidney Journal|2023|55